Literature DB >> 26808772

The Modified Girdlestone Procedure With Muscle Flap for Management of Pressure Ulcers and Heterotopic Ossification of the Hip Region in Spinal Injury Patients: A 15-Year Review With Long-term Follow-up.

Salah Rubayi1, Joubin Gabbay, Erwin Kruger, Kevin Ruhge.   

Abstract

BACKGROUND: Pressure ulceration, pyogenic arthritis, and hip heterotopic ossification are complications encountered in spinal cord injury patients. The Girdlestone procedure has been established as an effective treatment modality for hip pathology in this population and is particularly efficacious when a muscle flap is used to fill the femoral resection defect. We previously reported its use as a 3-stage procedure. Through time, experience was gained, and consequently, our technique has evolved to a 1-stage procedure.
METHODS: A retrospective analysis of all spinal cord injury patients who had undergone Girdlestone arthroplasty or excision of heterotopic ossification by the pressure ulcer management team at Rancho Los Amigos National Rehabilitation Center between 1991 and 2005 was performed. A description of our management, operative protocol, outcome, and complication is given.
RESULTS: Over 15 years (between 1991 and 2005), 295 patients underwent 330 procedures. Hips were operated for infection, heterotopic ossification, pressure ulceration, dislocation, femoral head necrosis, or fracture or a combination of the above. Twenty-five cases (7.6%) required surgical revision for wound breakdown in the immediate postoperative period. Average follow-up was 40.3 months; 43.6% of patients developed recurrence of ulceration requiring surgery. The average time until recurrence was 27.3 months.
CONCLUSIONS: The Girdlestone arthroplasty is an effective modality to treat hip infection, ankylosis, heterotopic ossification, dislocation, or other pathology associated with the spinal cord injury patient. Long-term follow-up of a large patient population reveals the efficacy of the procedure in preventing recurrence and improving patient quality of life.

Entities:  

Mesh:

Year:  2016        PMID: 26808772     DOI: 10.1097/SAP.0000000000000706

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  6 in total

1.  Treatments that are perceived to be helpful for non-neuropathic pain after traumatic spinal cord injury: a multicenter cross-sectional survey.

Authors:  Chung-Ying Tsai; Thomas N Bryce; Andrew D Delgado; Sara Mulroy; Bria Maclntyre; Susan Charlifue; Elizabeth R Felix
Journal:  Spinal Cord       Date:  2021-03-19       Impact factor: 2.772

2.  The modified bilobed flap for reconstructing sacral decubitus ulcers.

Authors:  Xiangong Jiao; Chunxiao Cui; Sally Kiu-Huen Ng; Zhangjia Jiang; Chihui Tu; Jiemin Zhou; Xiandong Lu; Xianwen Ouyang; Tong Luo; Ke Li; Yixin Zhang
Journal:  Burns Trauma       Date:  2020-12-12

3.  Hip resection arthroplasty for acute femoral neck fractures in the non-ambulator.

Authors:  Kevin Steelman; Nicholas Bolz; Jennifer Fleming; Rahul Vaidya
Journal:  OTA Int       Date:  2022-01-03

4.  Hip Joint Infections Caused by Multidrug-Resistant Enterobacterales Among Patients With Spinal Cord Injury: Experience of a Reference Center in the Greater Paris Area.

Authors:  B Davido; L Noussair; F El Sayed; K Jaffal; H Le Liepvre; D Marmouset; T Bauer; J L Herrmann; M Rottman; A C Cremieux; A Saleh-Mghir
Journal:  Open Forum Infect Dis       Date:  2022-04-17       Impact factor: 4.423

5.  Analysis of perioperative outcomes in hip resection arthroplasty.

Authors:  Alireza K Nazemi; Alexander Upfill-Brown; Armin Arshi; Troy Sekimura; Erik N Zeegen; Edward J McPherson; Alexandra I Stavrakis
Journal:  Arch Orthop Trauma Surg       Date:  2021-02-24       Impact factor: 2.928

Review 6.  The Survey of Cells Responsible for Heterotopic Ossification Development in Skeletal Muscles-Human and Mouse Models.

Authors:  Łukasz Pulik; Bartosz Mierzejewski; Maria A Ciemerych; Edyta Brzóska; Paweł Łęgosz
Journal:  Cells       Date:  2020-05-26       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.